NCT01012622
An Efficacy and Safety Study of Osmotic Release Oral System (OROS) Methylphenidate in Participants With Attention Deficit Hyperactivity Disorder (ADHD)
See it on ClinicalTrials.gov ↗136 people
17.6%
82.4%
24 womenmiddle line = equal numbers112 men
- Phase
- PHASE4
- Paid for by
- Janssen Korea, Ltd., Korea
- Finished
- 2009-08
- Health conditions
- Attention Deficit Disorder With Hyperactivity
- Who could join
- Anyone
- Ages
- 6 Years – 12 Years
- Average age
- mean 8.4 years
- Age 65+
- Not reported
- Weight (BMI)
- Not reported
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Not reported
Women left out
- Age limit under 65
Older women were turned away, even though they often take this medicine.
“Maximum age: 12 Years.”
- No mental health conditions
Women with depression, bipolar disorder or other mental health conditions were turned away.
“Participants who have significant suicidal ideation”
Study titles and rules are shown in their original English.